Peregrine Pharmaceuticals' Immuno-Oncology Agent Bavituximab to be Highlighted in Three Presentations at 2015 ASCO Annual Mee...
May 13 2015 - 5:00PM
Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a
biopharmaceutical company focused on advancing bavituximab, a novel
immuno-oncology agent in Phase III development, today announced the
presentation of three posters at the 2015 American Society of
Clinical Oncology (ASCO) Annual Meeting, to be held May 29-June 2,
2015 in Chicago, Illinois.
Abstract: 3059 Title:
Phosphatidylserine targeting antibody in combination with anti-PD-1
antibody treatment activates infiltrating T lymphocytes of the
spleen and tumor microenvironment in pre-clinical models of
melanoma and breast cancer Presenter: Xianming
Huang, Ph.D., The University of Texas Southwestern Medical Center
Session: Developmental Therapeutics—Immunotherapy
Track(s): Developmental Therapeutics and
Translational Research Session Type: General
Poster Session Time and Location: Saturday, May 30
8:00 AM - 11:30 AM CDT, S Hall A
Abstract: 3060 Title:
Activation of CD8+ tumor infiltrating lymphocytes by bavituximab in
a 3D ex vivo system of lung cancer patients
Presenter: Soner Altiok, M.D, Ph.D., H. Lee
Moffitt Cancer Center & Research Institute
Session: Developmental Therapeutics—Immunotherapy
Track(s): Developmental Therapeutics and
Translational Research Session Type: General
Poster Session Time and Location: Saturday, May 30
8:00 AM - 11:30 AM CDT, S Hall A
Abstract: 4109 Title: A phase
I/II study of bavituximab and sorafenib in advanced hepatocellular
carcinoma (HCC) Presenter: Adam Charles Yopp,
M.D., The University of Texas Southwestern Medical Center
Session: Gastrointestinal (Noncolorectal)
Cancer Track(s): Gastrointestinal (Noncolorectal)
Cancer Session Type: General Poster Session
Time and Location: Monday, Jun 1 8:00 AM -
11:30 AM CDT, S Hall A
In addition, Peregrine will be hosting ASCO conference attendees
at booth #22107.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company
with a pipeline of novel drug candidates in clinical trials for the
treatment and diagnosis of cancer. The company's lead immunotherapy
candidate, bavituximab, is in Phase III development for the
treatment of second-line non-small lung cancer (the "SUNRISE
trial") along with several investigator-sponsored trials evaluating
other treatment combinations and additional oncology indications.
The company is also advancing a molecular imaging agent,
124I-PGN650, in an exploratory clinical trial for the imaging of
multiple solid tumor types. Peregrine also has in-house cGMP
manufacturing capabilities through its wholly-owned subsidiary Avid
Bioservices, Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and third-party
customers. For more information, please visit
www.peregrineinc.com.
CONTACT: Christopher Keenan
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Sep 2023 to Sep 2024